Synthetic Biologics, Inc (AMEX:SYN) developer of therapeutics microbiome, is expected to report third quarter earnings results, after market close, on Tuesday 10th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.17 per share.
Looking ahead, the full year loss are expected at $ 0.65 per share.
Stock Performance
Shares of Synthetic Biologics, Inc traded low $ -0.02 or -5.53 percent on Monday, reaching $ 0.33 with volume of 217.80 thousand shares. Synthetic Biologics, Inc has traded high as $ 0.35 and has cracked $ 0.32 on the downward trend
According to the previous trading day, closing price of $ 0.33, representing a 40.00 % increase from the 52 week low of $ 0.25 and a 53.33 % decrease over the 52 week high of $ 0.75.
The company has a market capital of $ 6.42 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 5th October 2020, downgraded by Maxim Group to Hold from Buy rating.
Conference Call
Synthetic Biologics, Inc will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.syntheticbiologics.com
Synthetic Biologics, Inc., a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases, and monoclonal antibody therapies that prevents and treats pertussis.
